

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2019

<https://marketpublishers.com/r/HEA8404C981EN.html>

Date: December 2019

Pages: 39

Price: US\$ 2,000.00 (Single User License)

ID: HEA8404C981EN

Abstracts

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2019, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health) pipeline landscape.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) is acquired in the hospital setting. Symptoms include warm to the touch, fever and swollen, painful red bumps. Risk factors include being hospitalized, having an invasive medical device and residing in a long-term care facility. This can be prevented by antibiotics and following hygiene procedures.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Unknown stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health).

The pipeline guide reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hospital Acquired Methicillin-Resistant *Staphylococcus aureus* Infections (Women's and Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hospital Acquired Methicillin-Resistant *Staphylococcus aureus* Infections (Women's and Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant *Staphylococcus aureus* Infections (Women's and Male Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Methicillin-Resistant *Staphylococcus aureus* Infections (Women's and Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections (Women's and Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Overview

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Companies Involved in Therapeutics Development

Cesa Alliance SA

Destiny Pharma Plc

MGB Biopharma Ltd

Valevia UK Ltd

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Drug Profiles

AB-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGBBP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections -
Dormant Projects

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections -
Discontinued Products

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections -
Product Development Milestones

Featured News & Press Releases

Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-
BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-
Acquired Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Cesa Alliance SA, H2 2019

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Plc, H2 2019

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd, H2 2019

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2019

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects, H2 2019

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Cesa Alliance SA

Destiny Pharma Plc

MGB Biopharma Ltd

Valevia UK Ltd

I would like to order

Product name: Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/HEA8404C981EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HEA8404C981EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

